Tandem Diabetes Care Announces Upcoming Conference Presentations
Business Wire (Mon, 29-Apr 4:05 PM ET)
DexCom, Insulet, Tandem seen benefitting the most in diabetes survey - Wells Fargo
Seeking Alpha News (Mon, 29-Apr 9:24 AM ET)
Globe Newswire (Tue, 23-Apr 9:00 PM ET)
Tandem Diabetes Care to Announce First Quarter 2024 Financial Results on May 2, 2024
Business Wire (Tue, 9-Apr 4:05 PM ET)
Parexel Announces CEO Succession Plan
Globe Newswire (Mon, 18-Mar 9:05 AM ET)
Business Wire (Wed, 6-Mar 12:46 AM ET)
Tandem Diabetes Care Announces Proposed Private Placement of Convertible Notes
Business Wire (Mon, 4-Mar 4:05 PM ET)
Business Wire (Wed, 21-Feb 4:05 PM ET)
Business Wire (Tue, 13-Feb 8:30 AM ET)
Tandem Diabetes Care Inc designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. Nearly three quarters of total revenue is derived from the U.S., with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Tandem Diabetes Care trades on the NASDAQ stock market under the symbol TNDM.
As of April 30, 2024, TNDM stock price declined to $36.69 with 1,340,640 million shares trading.
TNDM has a beta of 1.55, meaning it tends to be more sensitive to market movements. TNDM has a correlation of 0.07 to the broad based SPY ETF.
TNDM has a market cap of $2.41 billion. This is considered a Mid Cap stock.
Last quarter Tandem Diabetes Care reported $197 million in Revenue and -$.27 earnings per share. This fell short of revenue expectation by $-7 million and missed earnings estimates by -$.02.
In the last 3 years, TNDM stock traded as high as $155.86 and as low as $13.82.
The top ETF exchange traded funds that TNDM belongs to (by Net Assets): IJR, VTI, VB, VXF, VBK.
TNDM stock has underperformed the market in the last year with a return of -7.3%, while SPY returned +22.3%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in TNDM shares. However, TNDM has outperformed the market in the last 3 month and 2 week periods, returning +57.0% and +15.2%, while SPY returned +2.5% and -0.5%, respectively. This indicates TNDM has been having a stronger performance recently.
TNDM support price is $35.70 and resistance is $38.40 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TNDM stock will trade within this expected range on the day.